Condition (MeSH)
Carcinoma, Islet Cell
ClinicalTrials.gov lists 71 trials for Carcinoma, Islet Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 14.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
38 of the 71 trials are tagged with Carcinoma, Islet Cell itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Islet Cell trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
| 2015 | 3 |
| 2014 | 5 |
| 2013 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 71 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Islet Cell trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 12 |
| Phase 1/2 | 1 |
| Phase 2 | 42 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Not applicable | 3 |
| Observational | 8 |
How many Carcinoma, Islet Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 4 |
| Completed | 47 |
| Terminated | 11 |
| Withdrawn | 5 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Islet Cell trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 14 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| ECOG-ACRIN Cancer Research Group | 3 |
| Novartis Pharmaceuticals | 3 |
| Eastern Cooperative Oncology Group | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Carcinoma, Islet Cell? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 7 |
| "Capecitabine" | 6 |
| Calcium Leucovorin | 5 |
| OXALIPLATIN | 3 |
| Temsirolimus | 3 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 6 |
| LAR Octreotide | 5 |
| Fluorouracile | 4 |
| Bevacizumab 1 | 4 |
| Sunitinib 4/2 | 3 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Islet Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 95 | 12 |
| Fatigue | 85 | 11 |
| Nausea | 72 | 12 |
| Vomiting | 64 | 14 |
| Diarrhea | 46 | 11 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Islet Cell? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. | Annals of surgical oncology | 2013 | Yes |
| First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. | Cancer | 2011 | Yes |
| Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. | Surgery | 2011 | Yes |
| The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2005 | Yes |
| Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2004 | Yes |
Showing 5 of 10 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.